Combination therapy with stem cell-derived immune cells boosts anti-cancer response

Cancer immunotherapy is built on a simple but powerful idea: the immune system can recognize and destroy cancer cells if it is properly activated. In many patients, however, this response is too weak or too slow to be effective. Recently, a type of immune cell called invariant natural killer T (iNKT) cells has attracted attention because of their ability to act as coordinators of immune responses, rapidly activating and rallying other immune cells to fight cancer.